LFVN vs USNA

For growth investors, LifeVantage Corporation (LFVN) is the stronger pick with 14.

2% revenue growth year-over-year, versus 8. 3% for USANA Health Sciences, Inc. (USNA). LifeVantage Corporation (LFVN) offers the better valuation at 6. 6x trailing P/E, making it the more compelling value choice. Analysts rate USANA Health Sciences, Inc. (USNA) a "Hold" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, LifeVantage Corporation (LFVN) is the cheapest at 6.

6x versus USANA Health Sciences, Inc. at 33. 6x.

Over the past 5 years, LifeVantage Corporation (LFVN) delivered a total return of -19.

4%, compared to -80. 0% for USANA Health Sciences, Inc. (USNA). Over 10 years, the gap is even starker: LFVN returned -42. 0% versus USNA's -68. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), LifeVantage Corporation (LFVN) is the lower-risk stock at 1.

12β versus USANA Health Sciences, Inc. 's 1. 34β — meaning USNA is approximately 20% more volatile than LFVN relative to the S&P 500. On balance sheet safety, USANA Health Sciences, Inc. (USNA) carries a lower debt/equity ratio of 2% versus 34% for LifeVantage Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), LifeVantage Corporation (LFVN) is pulling ahead at 14.

2% versus 8. 3% for USANA Health Sciences, Inc. (USNA). On earnings-per-share growth, the picture is similar: LifeVantage Corporation grew EPS 230. 4% year-over-year, compared to -73. 5% for USANA Health Sciences, Inc.. Over a 3-year CAGR, LFVN leads at 3. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

LifeVantage Corporation (LFVN) is the more profitable company, earning 4.

3% net margin versus 1. 2% for USANA Health Sciences, Inc. — meaning it keeps 4. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: USNA leads at 5. 5% versus 5. 3% for LFVN. At the gross margin level — before operating expenses — LFVN leads at 80. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, LFVN (3.

2% yield) pays a dividend. USNA does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, LifeVantage Corporation (LFVN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

12), 3. 2% yield). Both have compounded well over 10 years (LFVN: -42. 0%, USNA: -68. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Consumer Defensive sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: LFVN is a small-cap deep-value stock; USNA is a small-cap quality compounder stock. LFVN pays a dividend while USNA does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.